Vericel Co. (NASDAQ:VCEL) Director Robert L. Md Zerbe Sells 2,500 Shares of Stock

Vericel Co. (NASDAQ:VCEL) Director Robert L. Md Zerbe sold 2,500 shares of Vericel stock in a transaction on Wednesday, February 5th. The stock was sold at an average price of $62.50, for a total transaction of $156,250.00. Following the completion of the transaction, the director now owns 26,595 shares in the company, valued at $1,662,187.50. This trade represents a 8.59 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Vericel Trading Down 2.3 %

Shares of NASDAQ VCEL opened at $58.35 on Friday. Vericel Co. has a one year low of $39.12 and a one year high of $63.00. The business has a fifty day simple moving average of $57.84 and a 200 day simple moving average of $51.11. The firm has a market capitalization of $2.88 billion, a price-to-earnings ratio of 972.66 and a beta of 1.72.

Vericel (NASDAQ:VCEL) last released its quarterly earnings data on Thursday, November 7th. The biotechnology company reported ($0.02) EPS for the quarter, topping analysts’ consensus estimates of ($0.05) by $0.03. Vericel had a net margin of 1.56% and a return on equity of 1.48%. The company had revenue of $57.91 million during the quarter, compared to the consensus estimate of $55.32 million. On average, research analysts anticipate that Vericel Co. will post 0.14 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. FMR LLC raised its holdings in shares of Vericel by 1.0% in the 3rd quarter. FMR LLC now owns 2,372,812 shares of the biotechnology company’s stock worth $100,251,000 after buying an additional 22,461 shares in the last quarter. Conestoga Capital Advisors LLC grew its position in Vericel by 1.7% in the third quarter. Conestoga Capital Advisors LLC now owns 2,075,730 shares of the biotechnology company’s stock valued at $87,700,000 after acquiring an additional 34,360 shares during the period. Congress Asset Management Co. raised its stake in Vericel by 12.6% during the fourth quarter. Congress Asset Management Co. now owns 1,454,139 shares of the biotechnology company’s stock worth $79,847,000 after acquiring an additional 162,419 shares in the last quarter. GW&K Investment Management LLC lifted its holdings in shares of Vericel by 2.4% during the fourth quarter. GW&K Investment Management LLC now owns 1,273,964 shares of the biotechnology company’s stock valued at $69,953,000 after acquiring an additional 30,180 shares during the period. Finally, Geode Capital Management LLC boosted its stake in shares of Vericel by 0.8% in the 3rd quarter. Geode Capital Management LLC now owns 1,154,053 shares of the biotechnology company’s stock valued at $48,768,000 after purchasing an additional 9,613 shares in the last quarter.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently commented on the company. HC Wainwright reiterated a “buy” rating and issued a $60.00 price objective on shares of Vericel in a research note on Wednesday, January 15th. Truist Financial lifted their price target on Vericel from $61.00 to $67.00 and gave the stock a “buy” rating in a research report on Wednesday, December 18th. Canaccord Genuity Group increased their price objective on Vericel from $64.00 to $67.00 and gave the company a “buy” rating in a research report on Monday, February 3rd. BTIG Research boosted their target price on shares of Vericel from $56.00 to $66.00 and gave the stock a “buy” rating in a research report on Tuesday, November 26th. Finally, Stephens reissued an “overweight” rating and issued a $65.00 price target on shares of Vericel in a report on Wednesday, January 15th. One research analyst has rated the stock with a hold rating and seven have issued a buy rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $63.14.

Vericel Company Profile

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns.